Black checkmark with a sparkle and a curved line underneath on a white background.
Company

BlossomHill Therapeutics, Inc.

Ticker
BLSM
Sector
Industry
Report date
November 13, 2026
Valye AI Score

66

High visibility
Recent developments
Recent developments summary

Recent developments highlight BlossomHill's advancing clinical trials, regulatory progress, financial results, and stock performance influenced by trial data.

Recent developments:
  • BlossomHill announced plans to start the pivotal SOLARA-2 trial of BH-30643 in Q1 2027, leading to positive stock movement [N1].
  • The company reported a widened Q2 loss but noted advances in BH-30643 development and a strengthened balance sheet [N4].
  • BH-30643 showed a 45% response rate in EGFR C797S NSCLC patients, contributing to stock gains [N6].
  • BlossomHill received FDA Fast Track designation for BH-30643 in EGFR-mutant NSCLC, supporting regulatory progress [N8].
  • The company presented updated SOLARA data on BH-30643 in EGFR-mutant lung cancer, positively impacting stock sentiment [N7].
  • Recent news described BlossomHill as oversold, reflecting market volatility and investor sentiment [N2].
Overview

BlossomHill Therapeutics, Inc. is engaged in the development of targeted therapies for EGFR-mutant non-small cell lung cancer, with a lead candidate BH-30643. The company has reported clinical trial progress including a 45% response rate in patients with the EGFR C797S mutation and has received FDA Fast Track designation. Financial disclosures indicate a net loss and strong liquidity as of the latest quarter. The company is preparing to initiate a pivotal Phase 3 SOLARA-2 trial in Q1 2027.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. BlossomHill Therapeutics, Inc. is a biotechnology company focused on developing BH-30643 for EGFR-mutant NSCLC. The company has reported advancing clinical trials, including a planned pivotal SOLARA-2 trial in early 2027. As of September 30, 2026, BlossomHill held $224.9 million in cash and equivalents, with a net loss of $24.0 million for the quarter and strong liquidity ratios. Recent news highlights positive trial data and regulatory progress for BH-30643.

Scenarios for BLSM

Bull case model:

The company has demonstrated clinical activity with BH-30643 showing a 45% response rate in a difficult-to-treat mutation of NSCLC. FDA Fast Track designation and the upcoming pivotal SOLARA-2 trial initiation indicate advancing development milestones. Strong liquidity supports ongoing operations and trial execution. Positive trial data and regulatory progress could enhance the company's position in targeted lung cancer therapies.

Bear case model:

BlossomHill reported a net loss of $24.0 million in the latest quarter, reflecting ongoing development expenses without current revenue. The company remains dependent on clinical trial outcomes and regulatory approvals, which carry inherent risks. The biotech sector's volatility and competitive landscape for EGFR-mutant NSCLC therapies present execution and market risks. Financial sustainability beyond current cash reserves is a consideration.

Moat:

BlossomHill's moat is primarily based on its specialized focus on EGFR-mutant NSCLC and its lead drug candidate BH-30643, which has demonstrated promising clinical responses and received FDA Fast Track status. The company's clinical progress and regulatory designations provide potential competitive advantages in a niche oncology segment. However, as a clinical-stage biotech, the moat depends heavily on successful trial outcomes and regulatory approvals.

Risks overview
Risks summary
The primary risk is the uncertainty inherent in clinical development and regulatory approval of BH-30643, compounded by financial sustainability concerns.
Risks details:

• Clinical Trial Risk: The success of BH-30643 depends on clinical trial outcomes, which are uncertain and may not demonstrate sufficient efficacy or safety.
• Regulatory Risk: Regulatory approvals are required for commercialization; delays or denials could impact the company's prospects.
• Financial Risk: The company is currently operating at a loss and relies on cash reserves and potential financing to fund operations and trials.
• Competitive Risk: Other companies developing therapies for EGFR-mutant NSCLC may compete, affecting market share and pricing.

FINAL FORECAST FOR BLSM

Final take one line
BlossomHill Therapeutics shows advancing clinical development and strong liquidity but faces typical biotech risks related to trial outcomes and regulatory approvals.
Final take 12 to 24 month view

Business trends: Progress in clinical trials for BH-30643 and regulatory designations highlight focused development in EGFR-mutant NSCLC.
Execution milestones: Initiation of pivotal SOLARA-2 trial and continued data presentations are key near-term events.
Key risks: Clinical trial uncertainties, regulatory approval challenges, financial sustainability, and competitive pressures remain significant.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

66
LLM visibility overview
LLM Visibility known facts
  • BlossomHill Therapeutics, Inc. is a biotechnology company focused on developing therapies for EGFR-mutant non-small cell lung cancer (NSCLC).
  • The company is advancing BH-30643, a drug candidate targeting EGFR C797S mutation in NSCLC.
  • BH-30643 has shown a 45% response rate in EGFR C797S NSCLC patients as reported in September 2026.
  • BlossomHill has received FDA Fast Track designation for BH-30643 in EGFR-mutant NSCLC.
  • The company plans to start the pivotal SOLARA-2 trial of BH-30643 in Q1 2027.
  • Recent news indicates positive trial data and advancing clinical development of BH-30643.
  • As of September 30, 2026, BlossomHill reported cash and cash equivalents of $224.9 million.
  • The company reported a net loss of $24.0 million for the quarter ending September 30, 2026.
  • Basic and diluted earnings per share were -$1.29 for the same period.
  • Liquidity ratios as of September 30, 2026, include a current ratio of 5.42 and a cash ratio of 12.08, indicating strong liquidity.
  • The company’s current assets as of June 30, 2026, were $100.97 million and current liabilities were $18.62 million.
  • Recent news coverage highlights widening losses but strengthening balance sheet and advancing pipeline.
  • The company’s stock price was reported at $27.29 as of September 18, 2026.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-09 | www.nasdaq.com | BlossomHill To Start Pivotal SOLARA-2 Trial Of BH-30643 In Q1 2027; Stock Up | https://www.nasdaq.com/articles/blossomhill-start-pivotal-solara-2-trial-bh-30643-q1-2027-stock
  • N2 | 2026-11-02 | www.nasdaq.com | Blossomhill Therapeutics Becomes Oversold (BLSM) | https://www.nasdaq.com/articles/blossomhill-therapeutics-becomes-oversold-blsm
  • N3 | 2026-09-22 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - AMRX, BLSM, NEOG. NEO | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-amrx-blsm-neog-neo
  • N4 | 2026-09-18 | www.nasdaq.com | BlossomHill Q2 Loss Widens; BH-30643 Advances, Balance Sheet Strengthens | https://www.nasdaq.com/articles/blossomhill-q2-loss-widens-bh-30643-advances-balance-sheet-strengthens
  • N5 | 2026-09-17 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-blsm-18-positive-trial-data-adpt-ilmn-cbll-neog
  • N6 | 2026-09-15 | www.nasdaq.com | BlossomHill's BH-30643 Shows 45% Response In EGFR C797S NSCLC; Stock Up | https://www.nasdaq.com/articles/blossomhills-bh-30643-shows-45-response-egfr-c797s-nsclc-stock
  • N7 | 2026-09-15 | www.nasdaq.com | BlossomHill To Present Updated SOLARA Data On BH-30643 In EGFR-Mutant Lung Cancer Today; Stock Up | https://www.nasdaq.com/articles/blossomhill-present-updated-solara-data-bh-30643-egfr-mutant-lung-cancer-today-stock
  • N8 | 2026-09-09 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-phvs-7-roiv-6-trial-readouts-blsm-4-atrc-fth
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine